Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference
July 12 2021 - 7:00AM
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage
therapeutics company leveraging its proprietary XTreo™ platform to
enable precise, sustained, and local delivery of medications to the
ear, nose and throat (ENT) passages and other diseased tissues,
today announced that Maria Palasis, Ph.D., Lyra’s President and
Chief Executive Officer, will present at the William Blair Biotech
Focus Conference on Thursday, July 15, 2021 at 10:00 a.m. ET. A
live webcast of the fireside chat presentation will be available in
the Investor Relations section of the Company’s website at
https://investors.lyratherapeutics.com. The webcast replay will be
available for 30 days following the event.
About Lyra
Therapeutics
Lyra Therapeutics, Inc. is a clinical-stage
therapeutics company leveraging its proprietary XTreo™ platform to
enable precise, sustained, local delivery of medications to
diseased tissues not accessible with conventional therapeutic
approaches. Lyra’s XTreo™ platform is comprised of a biocompatible
mesh scaffold, an engineered elastomeric matrix and a versatile
polymer-drug complex. The company’s current pipeline of
therapeutics target tissues deep in the ear, nose and throat
passages and are designed to deliver continuous drug therapy for
months following a single non-invasive, in-office administration.
Lyra’s lead product candidate, LYR-210, is in late-stage clinical
development for the treatment of chronic rhinosinusitis and is
designed to deliver up to six months of continuous
anti-inflammatory drug therapy to the sinonasal passages. For more
information, please visit www.lyratherapeutics.com and
follow us on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements contained in this press release
that do not relate to matters of historical fact should be
considered forward-looking statements, including statements
regarding the company’s clinical advancement of LYR-210 for the
treatment of CRS. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause the company’s actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements, including, but not
limited to, the following: the fact that the company has incurred
significant losses since inception and expects to incur losses for
the foreseeable future; the company’s need for additional funding,
which may not be available; the company’s limited operating
history; the fact that the company has no approved products; the
fact that the company’s product candidates are in various stages of
development; the fact that the company may not be successful in its
efforts to identify and successfully commercialize its product
candidates; the fact that clinical trials required for the
company’s product candidates are expensive and time-consuming, and
their outcome is uncertain; the fact that the FDA may not conclude
that certain of the company’s product candidates satisfy the
requirements for the Section 505(b)(2) regulatory approval pathway;
the company’s inability to obtain required regulatory approvals;
effects of recently enacted and future legislation; the possibility
of system failures or security breaches; effects of significant
competition; the fact that the successful commercialization of the
company’s product candidates will depend in part on the extent to
which governmental authorities and health insurers establish
coverage, adequate reimbursement levels and pricing policies;
failure to achieve market acceptance; product liability lawsuits;
the fact that the company relies on third parties for the
manufacture of materials for its research programs, pre-clinical
studies and clinical trials; the company’s reliance on third
parties to conduct its preclinical studies and clinical trials; the
company’s inability to succeed in establishing and maintaining
collaborative relationships; the company’s reliance on certain
suppliers critical to its production; failure to obtain and
maintain or adequately protect the company’s intellectual property
rights; failure to retain key personnel or to recruit qualified
personnel; difficulties in managing the company’s growth; effects
of natural disasters; the fact that the global pandemic caused by
COVID-19 could adversely impact the company’s business and
operations, including the company’s clinical trials; the fact that
the price of the company’s common stock may be volatile and
fluctuate substantially; significant costs and required management
time as a result of operating as a public company and any
securities class action litigation. These and other important
factors discussed under the caption “Risk Factors” in the company’s
Quarterly Report on Form 10-Q filed with the SEC on May 11, 2021
and its other filings with the SEC could cause actual results to
differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking
statements represent management’s estimates as of the date of this
press release. While the company may elect to update such
forward-looking statements at some point in the future, it
disclaims any obligation to do so, even if subsequent events cause
its views to change.
Investor Contact:Argot
Partners212-600-1902argot@lyratherapeutics.com
Media Contact:Kathryn
Morris914-204-6412kathryn@theyatesnetwork.com
Lyra Therapeutics (NASDAQ:LYRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lyra Therapeutics (NASDAQ:LYRA)
Historical Stock Chart
From Apr 2023 to Apr 2024